Ectoin was not designed for faces. It is an extremolyte, a small molecule that bacteria living in Egyptian salt flats make in bulk to survive being dried, heated and irradiated, and it works by organising the water around a cell's proteins and lipids into an ordered shell that keeps them from denaturing when everything else goes wrong. German dermatology borrowed it two decades ago for eczema and irritated-skin creams at 1 to 7 percent, cosmetics borrowed it back at a tenth of that as a supporting act, and in 2025 it became the ingredient of the year. Paula's Choice's contribution to that year was to put it second in the list at a declared 7 percent — the top of the studied range and, at launch, the highest concentration in a mainstream product — and to call the result a booster. In 2026 the brand renamed it the 7% Ectoin + Hyaluronic Acid Milky Hydrating Serum, which is longer but more honest, because almost nobody was mixing it into anything. They were using it as the serum it is.
The number is the headline, but the emulsion is the achievement. A watery 7 percent ectoin solution would be a humectant gel with a famous name; this is a milky water-in-oil emulsion built from four light, dry-feeling esters — triethylhexanoin, diisopropyl adipate, isoamyl laurate, dicaprylyl carbonate — with squalane tenth and jojoba fifteenth as the skin-identical lipids, hydrogenated olive unsaponifiables for barrier support further down, and polyglyceryl emulsifiers holding it together. That structure matters because a damaged barrier is short of lipids as well as water, and ectoin's water-ordering shell is more useful when it forms around lipids that have been replaced. The formula delivers both in one step. Sodium hyaluronate sits sixteenth, marketed as a seven-weight complex, and pairs sensibly with the ectoin — one draws water, the other holds it in place — and glycogen, twentieth, is the third name on the label and the least consequential, a humectant with supplier data on barrier metabolism and not much else. There is no fragrance, no essential oil, no alcohol, no silicone and no dye; the preservative is hydroxyacetophenone with hexanediol. A very reactive face could read the list to the end and find nothing to object to.
What the serum does on the skin is what the emulsion predicts. It spreads with almost no drag, feels cool for a moment, and sets to a dewy, soft finish inside a minute — fast enough to go straight under sunscreen without pilling and light enough that combination and normal skin often need nothing over it. On tight, stinging, retinoid-flaky or freshly over-exfoliated skin the sting stops within that same minute, which is the moment most users become converts. Over the following days the flaking settles and the skin stops reacting to the weather, which is where the brand's claim — barrier visibly repaired in seven days, by its own instrumental testing — lands. That testing is unpublished, but the claim is consistent with what the dermatological literature on ectoin creams shows: reduced water loss, faster recovery from irritant damage, less erythema, on timescales of one to two weeks. The honest framing is that ectoin has good evidence as a barrier-supporting, anti-irritant molecule in medical creams and promising, thinner evidence as a cosmetic active at these doses, and that this formula is built well enough to give it the best chance.
Who it suits is nearly everyone, which is unusual. Dry, sensitive, rosacea-prone, post-procedure, retinoid-using and acid-using skin are the obvious audience; oily skin tolerates the ester film better than a cream and often uses it as its only hydration step. Very dry skin in winter is the one group that will want a cream over it, because 20 mL of a light emulsion is not an occlusive. It pairs with anything — it is, in effect, the product one reaches for on the nights the other products have gone too far.
The record after a year is strong: 385 reviews at 4.6 stars on the brand's site, Dermstore and Sephora listings, a NewBeauty 2026 award under the old name, and a consistent tone — calms instantly, doubles as a moisturiser, tolerated by the most reactive skin, expensive, confusing rename. That last point is fair. A product that changed its name mid-life while keeping its formula, and that is still shelved under boosters on the brand's site while being called a serum, has not made its own case as clearly as its ingredient list does.
Then the price, which is the only real argument against it. Forty-four dollars for 20 mL is serum money for a bottle that, at three or four drops twice a day, lasts six to eight weeks; a 10 mL trial size at half the price exists and is the sensible first purchase. Ectoin is a genuinely expensive fermentation-derived ingredient and 7 percent of it is a lot per bottle, so the cost is not arbitrary, and the brand's declared-dose positioning is a real service in a category where most ectoin products name the ingredient and hide the number. But it is still a premium, and a buyer whose skin is not compromised — who wants a nice hydrating serum rather than a barrier rescue — is paying for a molecule they do not particularly need at a dose that does not particularly matter to them.
For the skin that does need it, though, this is one of the more defensible premiums in the category: a survival molecule at its studied ceiling, in an emulsion that supplies the lipids to go with it, from a brand that prints the percentage on the box and leaves the irritants out. It will not transform a healthy face. It will make a damaged one stop hurting in a minute and start behaving in a week, and that is worth knowing the price of.
